Cabotegravir

卡替拉韦

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameCabotegravir
Drug Alias Nameカボテグラビルナトリウムcabotegravir sodium卡特雷韦Cabotegravir long actingCabotegravirum +[22] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHIV integrase inhibitors
TargetsHIV integrase
Therapy Area/IndicationsHepatitisHerpesviridae InfectionsHIV-Associated Lipodystrophy Syndrome +[4] 
Global Approved IndicationsHIV Infections
Approved Indications in ChinaHIV Infections
Original Approved Country/TerritoryCanada
Original Approved Date2020/03/18
Country/TerritoryCanadaBotswanaUnited States +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline PlcShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAfrica Health Research InstituteGlaxosmithkline PlcViiv Healthcare Bv +[9] 
Inactive CompaniesViiv Healthcare Pty LtdGlaxo Operations Uk LtdShionogi & Co Ltd +[4] 
Active IndicationsHIV Infections
Inactive IndicationsHepatitisHerpesviridae InfectionsHIV-Associated Lipodystrophy Syndrome

Other Information

ATC CodeJ05AR
Related LinksWikipediaDrugBankKEGG